CHICAGO -- Dendreon released some data related to its prostate cancer drug Provenge ahead of a data presentation here at the American Urological Association.
The data show that Provenge, the company's immunotherapy for prostate cancer, extended survival in a clinical trial by a median 4.1 months, reducing the risk of death by 22.5% in a 500-person study.
A press release from the AUA also states that the number of patients who are alive three years after treatment is 38% greater among those who received Provenge.
That difference is "marginal" in terms of statistical significance, says Donald Berry, a biostatistician at M.D. Anderson Cancer Center.
It's been over thirty years since a drug of this type has been approved by the FDA, so this is pretty major news.
Have a good Wednesday.
Blessings,
Rick
Wednesday, April 29, 2009
Subscribe to:
Post Comments (Atom)
1 comments:
I think it's great that there is so much research on medicines that can health or cure prostate cancer! But while we're still waiting on a cure, I definitely think eating foods like onions, soy, and fruits is a good way to protect one's self and keep a healthy prostate.
Post a Comment